Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | ERN1 | O75460 | 7/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501654 | 0.89 | ALDH1A1 (0.46) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL30129776 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL3647722 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL17747083 | 0.84 | ALDH1A1 (0.58) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL30153141 | 0.81 | ERN1 (0.77) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL3507686 | 0.81 | ALDH1A1 (0.61) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL28984395 | 0.81 | KDM4E (0.59) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL310771 | 0.81 | ERN1 (0.77) | ALDH1A1ERN1HCRTR1HCRTR2CA12 | |
| SCHEMBL5393044 | 0.80 | ALDH1A1 (0.64) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL29822834 | 0.80 | ALDH1A1 (0.64) | ALDH1A1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| CN-115315421-B | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4043460-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2024-06-05 | — | — | EP | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | ALDH1A1 263/4885ERN1 2699/4885HCRTR1 3942/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | ALDH1A1 1938/4885ERN1 2810/4885HCRTR1 3702/4885 |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | ALDH1A1 263/4885ERN1 2699/4885HCRTR1 3942/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | ALDH1A1 263/4885ERN1 2699/4885HCRTR1 3942/4885 |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | ALDH1A1 263/4885ERN1 2699/4885HCRTR1 3942/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | ALDH1A1 2000/4885ERN1 2536/4885HCRTR1 4532/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | ALDH1A1 3073/4885ERN1 1795/4885HCRTR1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.